1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,222 | 0,234 | 19:15 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.02. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 16.02. | VIVA BIOTECH (01873): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 29.01. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT APPROVAL OF ENVIRONMENTAL IMPACT REPORT FOR LANGHUA PHARMACEUTICAL | 1 | HKEx | ||
| 05.01. | VIVA BIOTECH (01873): UPDATE ANNOUNCEMENT REGARDING DEEMED DISPOSAL AND DISPOSAL OF EQUITY INTEREST IN VIVA SHANGHAI | - | HKEx | ||
| 29.12.25 | Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities | 242 | PR Newswire | SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader... ► Artikel lesen | |
| 15.12.25 | Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. | 434 | PR Newswire | STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which... ► Artikel lesen | |
| 02.12.25 | VIVA BIOTECH (01873): GRANT OF SHARE OPTIONS | 5 | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 29.09.25 | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 327 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| 25.09.25 | VIVA BIOTECH (01873): INTERIM REPORT 2025 | - | HKEx | ||
| 02.09.25 | Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights | 297 | PR Newswire | SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge... ► Artikel lesen | |
| 28.08.25 | Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth | 452 | PR Newswire | Financial Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage... ► Artikel lesen | |
| 15.05.25 | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 407 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 28.03.25 | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 453 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03.25 | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 245 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,742 | +0,25 % | Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva - von First Berlin Equity Research GmbH
25.02.2026 / 17:11 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt... ► Artikel lesen | |
| NOVONESIS | 50,08 | +0,46 % | Novozymes Reports Climb In Q4 Bottom Line | BRUSSELS (dpa-AFX) - Novozymes (NVZMF.PK) reported earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings came in at EUR122.8 million, or EUR1.25... ► Artikel lesen | |
| GENMAB | 251,00 | +1,91 % | Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise | The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as of 27 February 2026 in the ISIN below.
ISIN:
DK0010272202
Name:
Genmab
Volume... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,064 | +2,89 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 262,00 | -2,24 % | BeOne Medicines Ltd.: BeOne Medicines präsentiert Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2025 - weltweiter Erfolg von BRUKINSA und führende Rolle in der Onkologie | Weltweiter Umsatzerlös von 1,5 Milliarden US-Dollar und 5,3 Milliarden US-Dollar für das vierte Quartal und das Gesamtjahr, ein Anstieg von 33 bzw. 40 gegenüber den Vorjahresperioden Weltweiter... ► Artikel lesen | |
| SINO BIOPHARM | 0,632 | -1,71 % | Aktienmarkt: Aktie von Sino Biopharmaceutical tritt auf der Stelle (0,88 €) | Wenig Kursbewegung zur Stunde bei der Sino Biopharmaceutical-Aktie . Das Wertpapier notiert aktuell bei 0,88 Euro. Ein geringes Minus von 5,12 Prozent zeigt die Kurstafel für die Aktie von Sino Biopharmaceutical... ► Artikel lesen | |
| VERICEL | 30,000 | -0,66 % | Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results | Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,400 | +0,42 % | Moleculin Biotech, Inc.: Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) | Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,301 | -1,31 % | MustGrow Biologics und die Partnerschaft mit Bayer: Darum steht die Aktie erst am Anfang | Die globale Landwirtschaft steht vor einem Paradox. Sie muss mehr Menschen ernähren, aber mit weniger chemischen Mitteln. Weltweit sind in 162 Ländern inzwischen 460 Pestizide verboten oder eingeschränkt.... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 30,000 | -1,28 % | Sensei Biotherapeutics vergibt Aktienoptionen an 17 neue Mitarbeiter | ||
| ZAI LAB LTD ADR | 15,600 | -3,70 % | Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028 | ||
| BIOXCEL THERAPEUTICS | 1,378 | -2,27 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| REGENXBIO | 8,200 | +7,19 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| AKEBIA | 1,070 | -3,86 % | Akebia outlines 2026 pipeline expansion and expects Vafseo data catalysts in $1B dialysis market | ||
| ZEVRA THERAPEUTICS | 7,400 | -2,63 % | Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,222 Euro und damit -3,48 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.